临床综合试验的优势与挑战框架:专家小组报告

IF 3.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS American heart journal Pub Date : 2024-05-23 DOI:10.1016/j.ahj.2024.05.009
Anthony E. Peters MD , W. Schuyler Jones MD , Brian Anderson MD , Carolyn T. Bramante MD, MPH , Uli Broedl MD , Christoph P. Hornik MD, PhD, MPH , Lindsay Kehoe MS , Kirk U. Knowlton MD , Esther Krofah MPP , Martin Landray PhD, FRCP , Trevan Locke PhD , Manesh R. Patel MD , Mitchell Psotka MD, PhD , Frank W. Rockhold PhD , Lothar Roessig MD , Russell L. Rothman MD, MPP , Lesley Schofield BS , Norman Stockbridge MD, PhD , Anne Trontell MD, MPH , Lesley H. Curtis PhD , Adrian F. Hernandez MD, MHS
{"title":"临床综合试验的优势与挑战框架:专家小组报告","authors":"Anthony E. Peters MD ,&nbsp;W. Schuyler Jones MD ,&nbsp;Brian Anderson MD ,&nbsp;Carolyn T. Bramante MD, MPH ,&nbsp;Uli Broedl MD ,&nbsp;Christoph P. Hornik MD, PhD, MPH ,&nbsp;Lindsay Kehoe MS ,&nbsp;Kirk U. Knowlton MD ,&nbsp;Esther Krofah MPP ,&nbsp;Martin Landray PhD, FRCP ,&nbsp;Trevan Locke PhD ,&nbsp;Manesh R. Patel MD ,&nbsp;Mitchell Psotka MD, PhD ,&nbsp;Frank W. Rockhold PhD ,&nbsp;Lothar Roessig MD ,&nbsp;Russell L. Rothman MD, MPP ,&nbsp;Lesley Schofield BS ,&nbsp;Norman Stockbridge MD, PhD ,&nbsp;Anne Trontell MD, MPH ,&nbsp;Lesley H. Curtis PhD ,&nbsp;Adrian F. Hernandez MD, MHS","doi":"10.1016/j.ahj.2024.05.009","DOIUrl":null,"url":null,"abstract":"<div><p>The limitations of the explanatory clinical trial framework include the high expense of implementing explanatory trials, restrictive entry criteria for participants, and redundant logistical processes. These limitations can result in slow evidence generation that is not responsive to population health needs, yielding evidence that is not generalizable. Clinically integrated trials, which integrate clinical research into routine care, represent a potential solution to this challenge and an opportunity to support learning health systems. The operational and design features of clinically integrated trials include a focused scope, simplicity in design and requirements, the leveraging of existing data structures, and patient participation in the entire trial process. These features are designed to minimize barriers to participation and trial execution and reduce additional research burdens for participants and clinicians alike. Broad adoption and scalability of clinically integrated trials are dependent, in part, on continuing regulatory, healthcare system, and payer support. This analysis presents a framework of the strengths and challenges of clinically integrated trials and is based on a multidisciplinary expert “Think Tank” panel discussion that included representatives from patient populations, academia, non-profit funding agencies, the U.S. Food and Drug Administration, and industry.</p></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Framework of the strengths and challenges of clinically integrated trials: An expert panel report\",\"authors\":\"Anthony E. Peters MD ,&nbsp;W. Schuyler Jones MD ,&nbsp;Brian Anderson MD ,&nbsp;Carolyn T. Bramante MD, MPH ,&nbsp;Uli Broedl MD ,&nbsp;Christoph P. Hornik MD, PhD, MPH ,&nbsp;Lindsay Kehoe MS ,&nbsp;Kirk U. Knowlton MD ,&nbsp;Esther Krofah MPP ,&nbsp;Martin Landray PhD, FRCP ,&nbsp;Trevan Locke PhD ,&nbsp;Manesh R. Patel MD ,&nbsp;Mitchell Psotka MD, PhD ,&nbsp;Frank W. Rockhold PhD ,&nbsp;Lothar Roessig MD ,&nbsp;Russell L. Rothman MD, MPP ,&nbsp;Lesley Schofield BS ,&nbsp;Norman Stockbridge MD, PhD ,&nbsp;Anne Trontell MD, MPH ,&nbsp;Lesley H. Curtis PhD ,&nbsp;Adrian F. Hernandez MD, MHS\",\"doi\":\"10.1016/j.ahj.2024.05.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The limitations of the explanatory clinical trial framework include the high expense of implementing explanatory trials, restrictive entry criteria for participants, and redundant logistical processes. These limitations can result in slow evidence generation that is not responsive to population health needs, yielding evidence that is not generalizable. Clinically integrated trials, which integrate clinical research into routine care, represent a potential solution to this challenge and an opportunity to support learning health systems. The operational and design features of clinically integrated trials include a focused scope, simplicity in design and requirements, the leveraging of existing data structures, and patient participation in the entire trial process. These features are designed to minimize barriers to participation and trial execution and reduce additional research burdens for participants and clinicians alike. Broad adoption and scalability of clinically integrated trials are dependent, in part, on continuing regulatory, healthcare system, and payer support. This analysis presents a framework of the strengths and challenges of clinically integrated trials and is based on a multidisciplinary expert “Think Tank” panel discussion that included representatives from patient populations, academia, non-profit funding agencies, the U.S. Food and Drug Administration, and industry.</p></div>\",\"PeriodicalId\":7868,\"journal\":{\"name\":\"American heart journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American heart journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0002870324001248\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American heart journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002870324001248","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

解释性临床试验框架的局限性包括实施解释性试验的高昂费用、参与者的限制性准入标准以及冗余的后勤流程。这些局限性可能导致证据生成缓慢,无法满足人们的健康需求,产生的证据也不具有普遍性。临床综合试验将临床研究与常规护理相结合,是应对这一挑战的潜在解决方案,也是支持学习型医疗系统的机遇。临床综合试验的操作和设计特点包括范围集中、设计和要求简单、充分利用现有数据结构以及患者参与整个试验过程。这些特点旨在最大限度地减少参与和试验执行的障碍,减轻参与者和临床医生的额外研究负担。临床整合试验的广泛采用和可扩展性部分取决于监管机构、医疗系统和支付方的持续支持。本分析报告基于多学科专家 "智囊团 "小组的讨论,提出了临床整合试验的优势和挑战框架,该小组成员包括来自患者群体、学术界、非营利性资助机构、美国食品和药物管理局以及工业界的代表。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Framework of the strengths and challenges of clinically integrated trials: An expert panel report

The limitations of the explanatory clinical trial framework include the high expense of implementing explanatory trials, restrictive entry criteria for participants, and redundant logistical processes. These limitations can result in slow evidence generation that is not responsive to population health needs, yielding evidence that is not generalizable. Clinically integrated trials, which integrate clinical research into routine care, represent a potential solution to this challenge and an opportunity to support learning health systems. The operational and design features of clinically integrated trials include a focused scope, simplicity in design and requirements, the leveraging of existing data structures, and patient participation in the entire trial process. These features are designed to minimize barriers to participation and trial execution and reduce additional research burdens for participants and clinicians alike. Broad adoption and scalability of clinically integrated trials are dependent, in part, on continuing regulatory, healthcare system, and payer support. This analysis presents a framework of the strengths and challenges of clinically integrated trials and is based on a multidisciplinary expert “Think Tank” panel discussion that included representatives from patient populations, academia, non-profit funding agencies, the U.S. Food and Drug Administration, and industry.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
American heart journal
American heart journal 医学-心血管系统
CiteScore
8.20
自引率
2.10%
发文量
214
审稿时长
38 days
期刊介绍: The American Heart Journal will consider for publication suitable articles on topics pertaining to the broad discipline of cardiovascular disease. Our goal is to provide the reader primary investigation, scholarly review, and opinion concerning the practice of cardiovascular medicine. We especially encourage submission of 3 types of reports that are not frequently seen in cardiovascular journals: negative clinical studies, reports on study designs, and studies involving the organization of medical care. The Journal does not accept individual case reports or original articles involving bench laboratory or animal research.
期刊最新文献
Table of Contents Editorial Board Information for Readers Blood and urine metal levels in patients with diabetes and cardiovascular disease Response to Tomoyuki Kawada: Blood and urine metal levels in patients with diabetes and cardiovascular disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1